Breakoutwatch Weekly Summary 09/08/2023

You are receiving this email because you are or were a BreakoutWatch.com subscriber, or have subscribed to our weekly newsletter.
To read this newsletter on the site, click here: Newsletter .

Contents

The newsletter has been absent for a few weeks as I have concentrated on correcting some data problems introduced by a hack of the database. I believe all stock data is now correct and watchlist filters are working again. Next week I depart for 4 weeks on a European vacation but will try to produce this newsletter remotely.

Market Summary

Stocks rise on easing inflation fears

Hopeful signs on the inflation front helped the major benchmarks end with solid gains for the week, although stocks closed out their first negative month since February. A decrease in longer-term interest rates over much of the week provided a boost to growth shares in particular by reducing the implied discount on future earnings. Smaller-cap stocks outperformed, however, narrowing the significant year-to-date gap with large-caps. [more...]

Major Index Performance

Dow Jones
Last Close 34500.7
Wk. Gain -0.98 %
Yr. Gain 4.08 %
Trend Down
Dow Jones
S&P 500
Last Close 4451.14
Wk. Gain -1.31 %
Yr. Gain 15.52 %
Trend Up
S&P 500
NASDAQ Comp.
Last Close 13748.8
Wk. Gain -1.76 %
Yr. Gain 30.17 %
Trend Up
NASDAQ Comp.
Russell 2000
Last Close 13748.8
Wk. Gain 617.47 %
Yr. Gain 676.88 %
Trend Down
Russell 2000

Performance by Sector

Sector Wk. Change % Yr. Change % Trend
Consumer Discretionary -0.74 30.41 Up
Consumer Staples -0.72 -1.44 Down
Energy -0.37 6.48 Up
Finance -1.41 0.61 Up
Health Care -1.3 -2.21 Down
Industrials -2.46 11.51 Up
Technology -2.09 37.77 Up
Materials -2.71 5.09 Up
REIT -0.46 -0.7 Up
Telecom -0.71 32.67 Up
Utilities -0.06 -12.51 Down

Breakouts This Week Still Within 5% of Breakout Price (Limit 20 top C Score)

Watchlist Symbol Company Industry C Score* % Gain
SQZ MSFT Microsoft Corporation Software - Infrastructure 82.1 % 0.7 %
SQZ SLB Schlumberger N.V. Shell Companies 81.9 % 1.2 %
CWH BKR Baker Hughes Company Travel Services 81.8 % 2 %
CWH DAKT Daktronics, Inc. Electronic Components 79.6 % 3.4 %
SQZ ACGL Arch Capital Group Ltd. Insurance - Diversified 79 % 2.6 %
SQZ AEL American Equity Investment Life Holding Company Insurance - Life 76.3 % 0.5 %
SQZ BFAM Bright Horizons Family Solutions Inc. Personal Services 75.9 % 0.3 %
SQZ NOV NOV Inc. Information Technology Services 72 % 0 %
SQZ EMR Emerson Electric Company Specialty Industrial Machinery 71.6 % 1.2 %
SQZ PBF PBF Energy Inc. Banks - Regional 69.4 % 4.2 %
SQZ SG Sweetgreen, Inc. Restaurants 69.4 % 1.2 %
SQZ HES Hess Corporation Asset Management 69.3 % 0.7 %
SQZ ARGX argenx SE Biotechnology 68.2 % 0.7 %
SQZ PSTG Pure Storage, Inc. Computer Hardware 68.2 % 1.5 %
SQZ LOGI Logitech International S.A. Computer Hardware 67.8 % 2.9 %
SQZ DINO HF Sincl Restaurants 66.5 % 2 %
SQZ MIRM Mirum Pharmaceuticals, Inc. Biotechnology 64.9 % 4.3 %
SQZ ROIV Roivant Sciences Ltd. Biotechnology 63.8 % 0.1 %
SQZ GKOS Glaukos Corporation Medical Devices 62.7 % 2.5 %
SQZ EVI EVI Industries, Inc. Industrial Distribution 61.7 % 1.6 %
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage.

Breakdowns within 5% of Breakdown Price

Watchlist Symbol Company Industry C Score* % Loss
SS MYRG MYR Group, Inc. Medical Devices 80.1 % -3.3 %
SS STN Stantec Inc Semiconductors 74.2 % -0.5 %
SS VMC Vulcan Materials Company (Holding Company) Building Materials 73.8 % -2.2 %
SS VNT Vontier Corporation REIT - Office 70.1 % -1.8 %
SS MRK Merck & Company, Inc. Drug Manufacturers - General 64.1 % -1 %
SS ALOT AstroNova, Inc. Computer Hardware 62.6 % -0.2 %
SS TWO Two Harbors Investment Co REIT - Mortgage 62.4 % -0.1 %
SS ETNB 89bio, Inc. Biotechnology 59.8 % -0.8 %
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage.

Cup and Handle Chart of the Week

Aug. 16, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the achievement of First-Patient-In for the company-sponsored Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal melanoma (UM) patients.